Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men

Hypertension

Volumn 33, Issue 1 II, 1999, Pages 581-585

  Strachan, Fiona E ^a   Spratt, James C ^a   Wilkinson, Ian B ^a   Johnston, Neil R ^a   Gray, Gillian A ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Blood pressure; Endothelin; Endothelin receptor antagonist; Receptors, endothelin; Vasoconstriction

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; DRUG EFFECT; HEART INDEX; HEART RATE VARIABILITY; HEART STROKE VOLUME; HUMAN; HUMAN EXPERIMENT; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE; VASOCONSTRICTION; VASOMOTOR REFLEX;

EID: 0032898757     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.33.1.581     Document Type: Article

References (34)

1. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852-854.
2. Haynes WG, Ferro CJ, O'Kane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996;93: 1860-1870.
3. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-A receptor antagonist mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 1998;97:752-756.
4. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
5. Clarke JG, Benjamin N, Larkin SW, Webb DJ, Keogh BE, Davies GJ, Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol. 1989;257:H2033-H2035.
6. Pacher R, Bergler-Klein J, Globits S, Teufelsbauer H, Schuffer M, Krauter A, Ogris E, Rodler S, Nutte M, Hartter E. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol. 1993;71:1293-1299.
7. Koyama H, Nishizawa Y, Morii H, Tabata T, Inoue T, Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet. 1989;8645:991-992.
8. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990; 348:730-732.
9. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732-735.
10. Davenport AP, O'Reilly G, Molenaar P, Maguire JJ, Kuc RE, Sharkey A, Bacon CR, Ferro A. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J Cardiovasc Pharmacol. 1993;22(suppl 8):S22-S25.
11. Clozel M, Gray GA, Breu V, Löffler B, Osterwalder R. The endothelin ETB receptor mediates both vasodilatation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992;186:867-873.
12. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 1995;92:357-363.
13. Tsukahara H, Ende H, Magazine HI, Bahou WF, Goligorsky MS. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells: receptor coupling to nitric oxide synthase. J Biol Chem. 1994;269:21778-21785.
14. De Nucci G, Thomas R, D'Orleans Juste P, Antunes E, Walder C, Warner TD, Vane JR. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988;85:9797-9800.
15. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-1465.
16. Strachan FE, Haynes WG, Webb DJ. Endothelium-dependent modulation of venoconstriction to sarafotoxin S6c in human hand veins in vivo. J Cardiovasc Pharmacol. 1995;26(suppl 3):S180-S182.
17. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 1996a;94:2131-2137.
18. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, Nishikibe M, Yano M. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A. 1994;91:4892-4896.
19. Love MP, Ferro CJ, Haynes WG, Webb DJ, McMurray JJ. Selective or non-selective endothelin receptor blockade in chronic heart failure? Circulation. 1996b;94(suppl I):2899-2900. Abstract.
20. Gratton J-P, Cournoyer G, Loftier B-M, Sirois P, D'Orleans-Juste P. ETB receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Circulation. 1997;30:1204-1209.
21. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci. 1998;19:5-8.
22. Cowburn PJ, Cleland JGF, McArthur JD, MacLean MR, McMurray JJV, Dargie HJ. Short-term hemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. Lancet. 1998; 352:201-202.
23. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1 mediated vasocon-striction in severe chronic heart failure. Lancet. 1995;346:732-736.
24. Ferro CJ, Haynes WG, Hand MF, Webb DJ. The vascular endothelin and nitric oxide systems in essential hypertension. J Hypertens. 1996; 14(suppl 1):S50. Abstract.
25. Krum H, Viskoper RJ, Lacourcière Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338:784-790.
26. Reynolds EE, Hwang O, Flynn MA, Welch KM, Cody WL, Steinbaugh B, He JH, Chung F-Z, Doherty A. Pharmacological differences between rat and human endothelin B receptors. Biochem Biophys Res Commun. 1995;209:506-512.
27. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
28. Newby DE, Jalan R, Masumori S, Hayes PC, Boon NA, Webb DJ. Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc Res. 1998;38:221-228.
29. Wiinberg N, Walter-Larson S, Eriksen C, Nielsen PE. An evaluation of semi-automatic blood pressure manometers against intra-arterial blood pressure. J Ambul Monit. 1988;1:303-309.
30. Thomas SHL. Impedance cardiography using the Sramek-Bernstein method: accuracy and reproducibility at rest and during exercise. Br J Clin Pharmacol. 1992;34:467-476.
31. Zhu Y, Yang H-T, Endoh M. Negative chronotropic and inotropic effects of endothelin isopeptides in mammalian cardiac muscle. Am J Physiol. 1997;273:H119-H127.
32. Berrazueta JR, Bhagat K, Vallance P, MacAllister RJ. Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol. 1997;44:569-571.
33. Casino PR, Kilcoyne CM, Cannon RO III, Quyyumi AA, Panza JA. Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor. Am J Cardiol. 1995;75:40-44.
34. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO III. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995; 91:1732-1738.